Physical Plasma in Medicine
Plasma devices with hot plasma of about 70°C are used in gastroenterology and surgery e.g. for endoscopic oozing of internal hemorrhage as well as liver resection or polypectomies.
Plasmas for a direct therapeutically treatment of the human body are considerably colder. They are in the range of the body temperature. Numerous scientific studies on cold physical plasma proved strong antibacterial, anti-inflammatory and wound-healing supporting effects. In plasma different active components e.g. heat, UV radiation and electric fields.
Especially in poorly healing, chronic wounds cold plasma could be used supportively for wound treatment, because it destroys microorganisms and promotes wound healing by stimulating new tissue growth. Meanwhile medical application of cold physical plasma developed to an important new field of research: plasma medicine.
Besides a direct therapeutically application physical plasmas are also used in medicine for plasma-based decontamination and plasma-assisted modification of bio relevant surfaces. Surface modification and decontamination are indirect medical plasma applications. Here plasmatechnology is used to prepare materials or devices for medical applications.
New therapeutic approach for wound healing disorders and pathogen-induced skin diseases
A production of underDok filmproduction.
By the synergistic combination of different active plasma components like applying excited gas species (for example excited oxygen and nitrogen molecules), a low-level UV light irradiation, a current flow and a short topical increase in temperature a strong antimicrobial effect is generated at the surface treated by the plasma jet. This effect leads to a disruption of the cell membrane of typical wound pathogens and multiresistant bacteria.
Cold plasma treatment with the kINPen® MED is suitable in particular for chronic, infected wounds like Ulcus crusis or decubital ulcer, as well as skin diseases caused by pathogens, for example Acne vulgaris or Tinea pedis.
Wound healing is stimulated and accelerated by supporting cell proliferation during the treatment. Data from studies prove the high effectiveness on typical wound pathogens and multiresistant bacteria like Pseudomonas, Klebsiellae or Methicillin-resistant S.-aureus.
The plasma pen generates hand-warm plasma, which is very well tolerated, painless and easy to use. During the studies no side effects or resistance formation was observed.
The plasma jet kINPen® MED is easy to operate. After plug on the spacer, the plasma pen will be swept vertically over the affected skin area in a steady pace of about 5mm per second. The treatment will be repeated after a few days (one to two times per week) until the desired result is recognizable. The plasma treatment can and should be applied adjuvant to other forms of therapy like topical drug therapy or tissue excision depending on the treating physician advice.
Especially highly necrotic wounds first require a classic-mechanic debridement before cold plasma could be applied. To avoid unintended side effects we recommend applying the plasma treatment before a topical drug therapy.
Since 2005 several clinical studies or case studies about the application of cold plasma on skin and on acute and chronic wounds in Germany among others in Munich/Schwabing, Goettingen, Regensburg, Berlin and Greifswald were documented or published.
Up to now no unintended side effects were observed as a result of this type of plasma treatment. Differnet in vitro and in vivo investigations proved the high antimicrobial effect. Even on multi-resistant pathogens no clinical relevant differences were observed concerning the effectiveness:
• Effective against typical wound pathogens (Daeschlein G, et al., 2012):
• Destruction of all 105 investigated, typical wound germs and typical problem-causing pathogens like Pseudomonas, Klebsiellae, Methicillin-resistant S. aureus.
• Median of relative decreasing wound size in treatment of chronic leg ulcer (Ulrich C, et al., in publication): Treatment with kINPen® MED and Octenisept©: plasma therapy: 56 %, Octenisept© therapy: 19 %,
• Supporting cell proliferation by stimulation with cold plasma (Kalghatgi S, et al., 2010),
• Very well tolerated, no side effects of formation of resistance observed (Daeschlein G, et al., 2012)
For further information about clinical studies, case studies and publications please read the pdf-file.